Skip to Content
The largest U.S. drug distributor, like several of its competitors, remains under fire for its alleged role in America’s destructive opioid epidemic, as plaintiffs and prosecutors accuse it of hiding flaws in its supply chain that made it too easy for doctors to overprescribe and patients to abuse the drugs. In part as a result of a recent settlement with several states, McKesson reported a $4.5 billion loss for the fiscal year ended March 2021. After taking charge as a CDC-appointed centralized distributor for COVID vaccines in the U.S., McKesson had distributed about 246 million doses as of December 2021. McKesson’s oncology tech business, Ontada, joined MYLUNG to advance precision medicine for lung cancer patients.
Courtesy of McKesson
Lists ranking McKesson
Global 500 - 2022Aggregate sales hit $37.8 trillion last year—an in...READ MOREview in list
Fortune 500 - 2022This year’s Fortune 500 marks the 68th running of ...READ MOREview in list
World’s Most Admired Companies - 2022Just as it dominates our economy, Big Tech now dom...READ MOREview in list